GPR65 AS A THERAPEUTIC TARGET IN ALLERGIC AIRWAY INFLAMMATION

摘要

The disclosure identifies GPR65 as a protein target involved in the pathophysiology of allergic inflammation and describes a method for treating allergic inflammation by attenuating GPR65 expression or activity. GPR65 expression is shown to be significantly upregulated in a mouse model of allergic airway inflammation, and GPR65-deficient mice are demonstrated to display attenuated eosinophilia and IL-13 levels in response to an allergic challenge. The application further discloses that delivery of GPR65-specific antisense oligonucleotides, that are capable of reducing GPR65 expression in the lung, attenuate airway inflammation in response to allergic challenge.